Breast Cancer Treatment – Trastuzumab Biosimilars
Dr. William Flood, Chief Medical Officer for Eviti at NantHealth, discusses new significant findings from Eviti Connect, presented at the San Antonio Breast Cancer Symposium 2020, around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer. These findings show the promise of biosimilars as the oncology community continues to use them more to provide high-quality cancer care while lowering overall costs.
Dr. William Flood is the Chief Medical Officer for Eviti at NantHealth, a provider of enterprise solutions that help businesses transform complex data into actionable insights. Prior to his role within NantHealth, Dr. Flood has served as Assistant in Oncology at the Johns Hopkins Oncology Center, Assistant Professor and Associate Professor of Medicine at the Penn State College of Medicine. He is a multi-time graduate of Penn State (with a bachelor’s of science in molecular and cell biology and a master’s in health evaluation sciences) and earned his medical degree from the Temple University School of Medicine. He performed his post-graduate medical training at the Duke University Medical Center and the Johns Hopkins Oncology Center. While in active clinical practice, Dr. Flood was named a “Best Doctor in America” for many years.
